IMV Inc. is developing a new class of immunotherapies to treat cancer and working to make these therapies more effective and available.
Location: Canada, Nova Scotia, Dartmouth
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
| - | Horizon Te... | horizontec... |
Mentions in press and media 11
| Date | Title | Description |
| 12.11.2021 | IMV Inc. Announces Third Quarter 2021 Financial and Operational Update - Form 6-K | IMV Inc. Announces Third Quarter 2021 Financial and Operational Update Dartmouth, Nova Scotia, and Cambridge, Mass., November 10, 2021. IMV Inc. ("IMV" or "the Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company ... |
| 11.08.2021 | IMV : Strengthened financial position and extended cash runway with the completion of a $25M financing resulting in pro-forma cash and cash equivalents of $45.8 million on June 30th, 2021 (Form 6-K) | Strengthened financial position and extended cash runway with the completion of a$25M financing resulting in pro-forma cash and cash equivalents of $45.8 million onJune 30th, 2021 Completed the DeCidE1 Phase 2 clinical study in advanced, re... |
| 14.05.2021 | IMV INC. IMV : Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline (Form 6-K) | IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline Phase 2B study in r/r DLBCL to begin in Q2 of this year New investigator-initiated study of maveropepimut-S in breast cancer to b... |
| 14.05.2021 | IMV : Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline (Form 6-K) | IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline Phase 2B study in r/r DLBCL to begin in Q2 of this year New investigator-initiated study of maveropepimut-S in breast cancer to b... |
| 08.03.2021 | IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021 | DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Mar 8, 2021-- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold ... |
| 01.03.2021 | IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference | DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Mar 1, 2021-- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infecti... |
| 01.05.2020 | IMV Announces Proposed $22.3 Million Private Placement | DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private Placement”) of 7,797,203 units of the Company ... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands. Curr... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
Show more